Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)

Protalix BioTherapeutics' (PLX) quarterly Short term Debt came in at $20.4 million in Q2 2024, little changed quarter-over-quarter from $20.4 million in Q1 2024.

Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024) Analysis & Trends

Protalix BioTherapeutics' Short term Debt history runs 7 years deep, the most recent figure standing at $20.4 million for Q2 2024.

  • On a quarterly basis, Short term Debt changed N/A year-over-year to $20.4 million in Q2 2024; TTM through Jun 2024 was $20.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $20.3 million, changed N/A from the prior year.
  • Short term Debt steadied at $20.4 million in Q2 2024 per PLX's latest filing, from $20.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $56.4 million in Q2 2021 and bottomed at $3.2 million in Q3 2021.
  • The 4-year median for Short term Debt is $20.4 million (2024), against an average of $31.3 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Protalix BioTherapeutics 190.95 Mn 180.16 Mn 29.62 Mn

Historic Data

Download Data
DateValue
Jun 30, 2024 20.42 Mn
Mar 31, 2024 20.42 Mn
Dec 31, 2023 20.25 Mn
Sep 30, 2023 20.19 Mn
Sep 30, 2021 3.24 Mn
Jun 30, 2021 56.36 Mn
Mar 31, 2021 55.37 Mn
Dec 31, 2020 54.43 Mn
Mar 31, 2018 5.93 Mn
Dec 31, 2017 5.92 Mn
Sep 30, 2017 5.91 Mn
Dec 31, 2016 53.87 Mn